Clinical Trial: GC012F in Patients With Autoimmune Diseases

U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072884) titled 'GC012F in Patients With Autoimmune Diseases' on June 18.

Brief Summary: This is an open-label, early exploratory main clinical study to evaluate the safety and efficacy of GC012F Injection in subjects with autoimmune diseases (AID), as well as to assess its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.

Study Start Date: Aug. 18

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis (SSc) Idiopathic Inflammatory Myopathy (IIM)

Intervention: DRUG: GC012F injection

Subjects who meet the CAR-T cell infusion criteria will receive GC012F Injection infusion within 48-72 hours after completion of lymphodepleting precondit...